StockWatch
·

DABUR INDIA LTD. Q2 FY27 Results

DABURQ2 FY27 Results
Filing
Result:Steady· Market: Down#Margin squeeze

Beat/Miss: Inline · Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue3.6K5.3%11.7%
Total Income3.7K5.1%12.1%
Expenditure3.1K2.9%12.0%
PBT645.5214.6%12.6%
Net Profit498.5714.9%12.1%
OPM—
NPM13.35%1.54pp0.00pp
EPS2.8514.4%11.8%
View full financials

FMCG revenue/PAT grew low-double-digits in line with plan but operating margin compressed ~68bps YoY on cost growth outpacing revenue, so quality is ordinary despite the headline growth.

DABUR INDIA · Q2 FY27 · THE VERDICT

Double-Digit Growth Holds, but Momentum Fades—And Margins Don't Expand

Dabur delivered on FY27 guidance with +11.6% revenue and +12.1% PAT, confirming its second consecutive double-digit quarter. Yet QoQ weakness (revenue -5.3%, PAT -14.9%) and stalled margin expansion—despite Q1 promises—signal momentum loss and execution risk on a nascent CEO strategy.

10 Nov 2026 · 6 min read

The quarter at a glance

Consolidated Revenue

₹3,563 Cr

+11.6% YoY; -5.3% QoQ

PAT

₹499 Cr

+12.1% YoY; -14.9% QoQ

NPM

13.3%

Margin diluted 10 bps YoY

India FMCG

+10.7%

Volume 5.5%, pricing 5.2%

Dabur's Q2 earnings read as a paradox: on the full-year lens, the company is on track; on the quarter's own momentum, it is losing steam. Consolidated revenue of ₹3,563 Cr and PAT of ₹499 Cr confirm the FY27 double-digit guidance reaffirmed in Q1—the second consecutive double-digit revenue quarter and the fourth such PAT quarter. But the QoQ decline—revenue down 5.3%, PAT down 14.9%—signals either Q1 was unusually strong or Q2 faced unexpected headwinds. Management cited HPC (Home & Personal Care) cost inflation. What matters more is the outcome: margins defended, not expanded. The Q1 call promised 'margins better YoY through pricing, premiumization, and cost discipline.' Q2 reality: India stand-alone margin diluted 10 bps YoY. That gap—between the promised expansion and the actual defense—is the quarter's defining tension.

Where the profitability really stands

The reported NPM of 13.3% masked two offsetting forces. Pricing power was real: India FMCG delivered 5.2% pricing in an inflationary environment. Volume held at 5.5% growth. But HPC cost inflation was relentless: supply chain and freight pressures forced the company into mitigation mode, not pass-through. CEO Herjit Bhalla framed it as 'controlling the controllables'—a measured tone that signals margin pressure ahead, not margin recovery. Operating efficiencies (₹115 Cr generated; target ₹170–200 Cr) are entirely earmarked for growth reinvestment, not profit expansion. Geopolitical upside (crude, freight normalization) was mentioned only as a 'next fiscal' possibility, not a Q2 tailwind. The implication: near-term margin expansion is off the table. Dabur is in margin defense and reinvestment mode, defending its Q2 result against a macro headwind, not riding a structural profit upswing.

Management's claims: What holds up

Verified against delivered result and prior guidance

'11.6% consolidated growth, 2nd consecutive double-digit revenue quarter'

Delivered or not in results

Revenue ₹3,563 Cr, +11.6% YoY confirmed. QoQ -5.3% not volunteered.

Verdict

Supported (YoY holds; QoQ decline obscured)

'Managed strong PAT despite inflation; only 10 bps dilution'

Delivered or not in results

PAT ₹499 Cr +12.1% YoY, NPM 13.3% YoY. Q1 promised margin expansion via pricing/premiumization; actual is margin defense.

Verdict

Overstated (expansion promise not met)

'Premium portfolio 17% → 20%, growing 4X overall rate, target 23% in 18 months'

Delivered or not in results

Not itemized in results. Management narrative only; specific growth rate unverified.

Verdict

Plausible but unverified (mix shift credible; granular metrics not in filings)

'India FMCG 10.7%, volume 5.5%, pricing 5.2%'

Delivered or not in results

Not itemized in results release. India standalone 8.9% disclosed.

Verdict

Unverified (sub-segment detail not in filings)

'Project Saksham: 43% distributor cut, 80% ROI uplift, GT back to growth—highest in 19 quarters'

Delivered or not in results

GT back to growth confirmed. Distributor count and ROI uplift numbers not in results.

Verdict

Unverified (GT recovery confirmed; execution detail not disclosed)

What changed on this call

Three material shifts from Q1 to Q2:

  • New CEO strategy unfolds publicly: Herjit Bhalla (6 months in, ex-MNC background) rolled out a structured 7-pillar 'Vision 7' (premiumization, distribution, health/wellness, M&A, core brands, GT expansion, digital). Early wins are real (premiumization +3 points YoY, GT back to growth). Full roadmap and FY27/FY28 targets deferred to mid-term review 6–8 months out. This is a strategic step-change, not an incremental refinement.

  • Margin guidance tone shifted from expansion to defense: Q1 promised 'better YoY margins.' Q2 delivered defended margins with 10 bps dilution. No quantified margin target disclosed going forward. Cost mitigation and pricing are coping tools, not profit accelerators.

  • Premiumization locked in as a real, measurable anchor: Mix 17% → 20%, growing 4X company rate, targeting 23% within 18 months. This is a concrete pillar investors can track and verify each quarter.

How the street positioned itself—and what it thought of the result

Price action told the street's verdict clearly: the stock sold off -2.53% on day 1 of the result announcement (from a pre-result close of ₹395) and deteriorated further to -5% by day 3. At ₹375.25 (as of 2026-11-09), the stock sits below its 50-day average (₹379.33) and markedly below its 200-day (₹432.59). Now trading 44% below its all-time high, RSI at 48.2 (neutral), but volume increasing—selling on conviction, not panic.

Ownership flows confirm the skepticism: FII ownership has contracted from 12.68% (Q1 FY26) to 9.66% (Q1 FY27), a steady three-point exit over four quarters. This quarter, FII trimmed another -0.32pp. Domestic institutional investors added +0.16pp, but DII alone cannot offset the foreign investor drift. Promoter holding stable at 66.24% rules out an insider dump, but the FII compression is the tell: global investors have been exiting into a 44% drawdown for a sustained period.

The market's working theory: Dabur confirmed guidance (not a miss), displayed real strategy progress (premiumization, GT), and holds a 142-year franchise moat. But guidance-matching without upgrade, margin defense instead of expansion, QoQ momentum loss, and a new-CEO playbook that won't disclose full targets until 6–8 months out—all in an environment where FII are exiting—reads as 'Hold pending clarity.' The stock's 44% drawdown from ATH should, in isolation, tempt contrarian buyers; the post-result selling into that drawdown suggests the market views the valuation as a risk, not a gift, until execution proves out.

Risks—ranked by how much they should concern a holder

Execution risk on new CEO strategy; mid-term visibility deferred 6–8 months

High

Herjit Bhalla is 6 months in. Full roadmap, FY27/FY28 targets, and capex plan withheld until mid-term review. Premiumization and GT are real, but nascent. If targets disappoint or timeline slips when revealed, FII outflow accelerates and valuation re-rates lower.

QoQ momentum loss signals underlying weakness

High

Revenue -5.3% QoQ, PAT -14.9% QoQ. Management did not disclose Q1 strength or Q2 headwinds explicitly. If the trend continues into Q3, double-digit FY27 guidance will be at risk. Momentum is the street's proxy for execution credibility.

Healthcare segment weak at 6.9% growth; recovery unproven

Medium

Portfolio average 11.6% growth; healthcare only 6.9%. Management cites recovery from COVID lows, but 6.9% is a lag, not a recovery. Chyawanprash flat for 3–4 years post-COVID. If revival initiatives don't inflect soon, healthcare becomes a structural drag on portfolio growth.

Margin expansion off the table; only geopolitical upside remains

Medium

Q1 promised margin expansion via pricing/premiumization/cost discipline. Q2 delivered margin defense only, 10 bps dilution YoY. Upside now gated on crude/commodity price relief (speculative) and reinvestment cycle completion (12+ months). Structural margin recovery is not in sight.

Sesa acquisition integration (go-live Dec 2026); success not yet visible

Medium

Acquisition retroactive to Apr 2026; integration go-live Dec 2026. M&A is a stated pillar of growth strategy. If integration falters or nutraceutical growth disappoints post-integration, management's M&A thesis erodes.

FII outflow trend sustained (down 3pp in 4 quarters)

Low-Medium

Ownership compression signals sustained skepticism. Continued outflow could pressurize valuation even if fundamentals hold. Risk is secondary to execution—if strategy delivers, flows reverse. But flow trends matter for stock momentum.

The bull-bear ledger

  • Delivered on FY27 double-digit guidance; YoY growth solid (+11.6% rev, +12.1% PAT, now fourth double-digit PAT quarter)

  • Premiumization pillar working: mix 17% → 20%, growing 4X company rate; target 23% in 18 months is measurable

  • Project Saksham (distribution consolidation) de-risking GT expansion: GT back to growth after 2 quarters, 'highest in 19 quarters' claimed

  • Operating efficiencies generating real cash: ₹115+ Cr to date; ₹170–200 Cr targeted for reinvestment buffer

  • New CEO strategy coherent in design; early wins tangible; board backing clear

  • QoQ momentum fading sharply: revenue -5.3%, PAT -14.9% QoQ suggests either Q1 was unusually strong or Q2 faced unexpected headwinds

  • Margin expansion promise walked back (Q1 'better YoY' → Q2 'defended'); no quantified margin target disclosed going forward

  • Healthcare segment lagging at 6.9% vs portfolio 11.6%; Chyawanprash flat 3–4 years; revival complex and unproven

  • CEO strategy nascent; full roadmap and FY27/FY28 targets deferred 6–8 months; late-stage visibility risk high

  • FII outflow sustained (down 3pp over 4 quarters, -0.32pp this quarter); ownership compression a concern for stock momentum

What to watch next

  • 1 · Q3 QoQ momentum—the inflection signal

    The day 1 and day 3 sell-off (-2.53%, -5%) telegraphs street concern about momentum loss. If Q3 revenue and PAT reverse the QoQ decline—even modestly—it resets the narrative and validates that Q2 was a speed bump. If they continue downward, the momentum fade thesis gains traction and FY27 double-digit guidance credibility erodes.

  • 2 · Mid-term strategy roadmap (expected 6–8 months)

    Herjit Bhalla explicitly deferred full 2031 vision and FY27/FY28 targets to this update. Credible targets (15%+ growth, margin expansion timelines, capex runways) will restore FII confidence and reset the valuation debate. Vague or defensive guidance extends the overhang and likely accelerates outflow.

  • 3 · Healthcare and Chyawanprash inflection signal

    At 6.9% growth, healthcare is a portfolio drag. Management outlined a multi-pronged turnaround (purity/traceability via monofloral honey, premiumization, occasion-based sampling, OTC/digestive expansion, Sesa integration by Dec 2026). Early wins in Q3/Q4 (gummy uptake, regional honey sourcing traction, OTC double-digit growth) will signal whether the revival thesis is credible or a management hope.

The single number to track

Dabur is a steady execution story with a credible new strategy and real near-term wins (premiumization, distribution, efficiencies). But it is not a buy-the-dip story yet. The QoQ momentum fade (-5.3% revenue, -14.9% PAT), the stalled margin expansion despite Q1 promises, and the deferred visibility on CEO targets all argue for patience. The market's post-result sell-off (day 1 -2.53%, day 3 -5%) and sustained FII outflow reflect the street's caution. The single metric to track from Q3 forward is organic PAT growth, quarter-on-quarter. If it returns to positive sequential growth, momentum resets and validates that Q2 was temporary. If it continues downward, it suggests broader softening and the double-digit FY27 guidance could slip. Watch that number next quarter. The rating is Hold until the mid-term roadmap lands (6–8 months) with specific targets and the Q3 QoQ trend clarifies. Margin recovery is off the table for near term; the story now is execution risk on strategy, not earnings upside.

Informational and educational content only. Not investment advice.